← Back to Search

Understanding Physiological and Psychological Mechanisms in Eating Disorders

N/A
Recruiting
Led By Katherine J Forney, PhD
Research Sponsored by Ohio University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female
Aged between 18 to 40 years old
Must not have
Medical conditions that affect appetite or weight
Specific phobia, blood-injection-injury type
Timeline
Screening 3 weeks
Treatment Varies
Follow Up -10 minutes, 0 minutes (immediately after the intervention), 10 minutes, 20 minutes, 30 minutes, 60 minutes and 90 minutes post-intervention
Awards & highlights

Summary

This trial will test if fear, gut peptides, and feeling full affect eating disorders and GI distress.

Who is the study for?
This trial is for women aged 18-40 with a DSM-5 diagnosed eating disorder, feeling sick or having stomachaches after eating sometimes. They should have a BMI between 18.5 and 26.5 and experience significant distress or impairment from their condition. It's not for those with conditions affecting appetite/weight, recent/current pregnancy, dairy/strawberry/honey allergies, or specific blood-injection-injury phobias.
What is being tested?
The study examines how changing the description of a test meal affects fear responses, gut hormone levels, and feelings of fullness in individuals with eating disorders to understand gastrointestinal distress and maintenance of these disorders.
What are the potential side effects?
Since this trial involves psychological assessments rather than medication, side effects may include emotional discomfort due to discussing personal experiences related to eating disorders.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am female.
Select...
I am between 18 and 40 years old.
Select...
I have been diagnosed with an eating disorder.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition that affects my appetite or weight.
Select...
I have a severe fear of seeing blood or getting injections.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~-10 minutes, 0 minutes (immediately after the intervention), 10 minutes, 20 minutes, 30 minutes, 60 minutes and 90 minutes post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and -10 minutes, 0 minutes (immediately after the intervention), 10 minutes, 20 minutes, 30 minutes, 60 minutes and 90 minutes post-intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cholecystokinin response
Gastrointestinal distress
Peptide YY response
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Low Fat Yogurt - High Fat YogurtExperimental Treatment1 Intervention
Participants will eat yogurt described as 'low fat' at Study Visit 2 and yogurt described as 'high fat' at Study Visit 3.
Group II: High Fat Yogurt - Low Fat YogurtExperimental Treatment1 Intervention
Participants will eat yogurt described as 'high fat' at Study Visit 2 and yogurt described as 'low fat' at Study Visit 3.

Find a Location

Who is running the clinical trial?

Ohio UniversityLead Sponsor
70 Previous Clinical Trials
37,046 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,869 Previous Clinical Trials
2,777,384 Total Patients Enrolled
62 Trials studying Eating Disorders
24,236 Patients Enrolled for Eating Disorders
Katherine J Forney, PhDPrincipal InvestigatorOhio University

Media Library

High Fat Yogurt - Low Fat Yogurt Clinical Trial Eligibility Overview. Trial Name: NCT05382702 — N/A
Eating Disorders Research Study Groups: High Fat Yogurt - Low Fat Yogurt, Low Fat Yogurt - High Fat Yogurt
Eating Disorders Clinical Trial 2023: High Fat Yogurt - Low Fat Yogurt Highlights & Side Effects. Trial Name: NCT05382702 — N/A
High Fat Yogurt - Low Fat Yogurt 2023 Treatment Timeline for Medical Study. Trial Name: NCT05382702 — N/A
~14 spots leftby Dec 2024